Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Revenue of Arcutis Biotherapeutics, Inc. (ARQT)
Revenue in 2023 (TTM): $59.61 M
According to Arcutis Biotherapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $59.61 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Arcutis Biotherapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $59.61 M | $54.62 M | $-227,434,000 | $-259,027,000 | $-262,140,000 |
| 2022 | $3.69 M | $2.93 M | $-294,553,000 | $-311,458,000 | $-321,289,000 |
| 2021 | $ | $-763,000 | $-205,593,000 | $-206,356,000 | $-205,902,000 |
| 2020 | $ | $-455,000 | $-135,223,000 | $-135,678,000 | $-135,678,000 |
| 2019 | $ | $-195,000 | $-41,801,000 | $-41,996,000 | $-41,996,000 |
| 2018 | $ | $ | $480 K | $-19,255,000 | $-19,255,000 |
| 2017 | $ | $ | $-872,000 | $-4,978,000 | $-4,978,000 |